VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IRMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IRMDIRadimed Corporation
$82.31$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIRMDCash Flow

IRadimed Corporation (IRMD) Cash Flow Statement

14Y historyFree accessUpdated daily

Operating cash flow of $7.0M in Q3 2026 exceeded net income of $6.5M, with free cash flow margin at 28.4%, while cash returns through roughly $2.6M in quarterly dividends and no buybacks suggest a conservative capital allocation posture that warrants continued monitoring of working capital swings.

Income StatementBalance SheetCash FlowRatios

IRMD Cash Flow Statement

Annual statement

IRMD Cash Flow Statement

IRadimed Corporation (IRMD) cash flow statement — 14-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash from Operations27.15M24.95M25.62M13.47M10.04M11.26M5.82M10.23M7.38M3.42M9.41M7.65M2.59M1.47M1.51M
Operating CF Margin %-29.76%34.99%20.54%18.84%26.92%18.34%26.57%24.23%14.8%28.95%24.21%16.52%13%19.64%
Operating CF Growth %68.91%-2.64%90.3%34.08%-10.8%93.52%-43.15%38.73%115.93%-63.68%22.97%195.83%75.37%-2.3%-
Net Income23.98M22.48M19.23M17.19M12.83M9.33M1.37M9.63M6.3M499.76K7.21M7.53M2.05M1.94M966.09K
Depreciation & Amortization1.66M1.17M817.66K765.18K670.67K1.41M1.34M1.24M1.11M1.31M248.3K223.94K149.06K139.04K106.28K
Stock-Based Compensation2.96M2.92M2.52M2.19M1.39M1.46M3.96M1.85M1.76M2.45M1.84M1.22M724.06K271.92K173.24K
Deferred Taxes133.53K0-697.65K-1.17M57.1K523.61K389.93K-596.75K-144.43K-150.66K-570.91B-16.12K-167.31K00
Other Non-Cash Items1.96M2.73M-3.02K402.32K148.74K119.04K-70.07K68.69K155.66K424.97K570.91B-1.6M229.37K-651.55K-430
Working Capital Changes-3.55M-4.34M3.75M-5.91M-5.06M-1.58M-1.17M-1.97M-1.81M-1.12M514.35K290.3K-399.83K-873.45K263.98K
Change in Receivables90.43K-3.03M1.76M841.91K-8.24M-575.54K2.69M-3.11M-446.9K-201.59K75.3K-1.91M21.87K-396.59K-1.15M
Change in Inventory-2.29M-1.38M3.13M-7.47M-1.31M-393.32K-282.9K123.68K-121.59K-334.11K-1.48M-308.41K-847.58K45.66K-116.83K
Change in Payables85.93K-76K-861.62K-216.44K1.12M30.41K-403.57K149.32K34.16K-523.45K1.11K376.29K201.69K19.05K337.32K
Cash from Investing-1.54M-8.42M-8.82M-8.01M-1.37M648.24K246.97K3.2M1.52M-1.02M-1.94M-61.47K-8.3M-196.75K-166.27K
Capital Expenditures-1.01M-7.76M-8.01M-7.44M-823.02K-482.32K-636.75K-368.28K-264.67K-824.76K-1.52M-314.84K-606.29K-191.76K-161.56K
CapEx % of Revenue1.13%9.26%10.93%11.35%1.54%1.15%2.01%0.96%0.87%3.57%4.69%1%3.87%1.69%2.1%
Acquisitions0000000036.35K49.19K743.49K022.31K00
Investments---------------
Other Investing-528.23K-656K-811.75K-566.66K-1.05M-259.43K0-117.53K-36.35K-49.19K-743.49K237.25K-22.31K-33.57K-53.33K
Cash from Financing-18.85M-17.6M-14.34M-13.66M-12.71M24.43K522.48K2.02M929.87K-1.9M-9.12M2.33M12.71M-513.4K-238.53K
Debt Issued (Net)000000000000-6.33K00
Equity Issued (Net)0029.62K0001.73M00-1.82M-9.97M014.49M00
Dividends Paid-16.23M-15.04M-13.68M-13.22M-12.56M0000000000
Share Repurchases00000000-309.56K-1.82M-9.97M0000
Other Financing-2.62M-2.56M-688.16K-433.6K-147.27K24.43K-1.21M2.02M929.87K-81.77K850.69K2.33M-1.77M-513.4K-238.53K
Net Change in Cash6.76M-1.07M2.47M-8.2M-4.04M11.93M6.59M15.45M9.82M492.11K-1.65M9.91M6.99M764.25K1.1M
Free Cash Flow25.95M17.18M17.62M5.46M8.17M10.52M5.18M9.75M7.11M2.59M7.88M7.33M1.98M1.28M1.35M
FCF Margin %29.05%20.5%24.06%8.32%15.32%25.15%16.33%25.31%23.36%11.23%24.25%23.21%12.65%11.31%17.54%
FCF Growth %81.52%-2.48%222.83%-33.18%-22.33%102.99%-46.85%37.06%174.45%-67.13%7.47%270.54%54.33%-4.82%-
FCF per Share2.021.341.380.430.650.840.420.790.590.220.660.580.190.120.13
FCF Conversion (FCF/Net Income)1.08x1.11x1.33x0.78x0.78x1.21x4.25x1.06x1.17x6.84x1.30x1.02x1.26x0.76x1.56x
Interest Paid000000000000000
Taxes Paid3.38M3.92M6.51M5.35M1.71M970K012K1.38M1.21M3.39M2.7M1.18M1.39M0

Key Metrics

Growth RegimeMixed
ProfitabilityStrong
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Quarterly OCF volatility and conversion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Conversion Runs Above Earnings

Based on reported figures, IRMD's operating cash flow exceeded net income in most recent quarters, with OCF/NI ratios of 1.08, 1.14, and 1.42 across Q3 2026, Q2 2026, and Q1 2026 respectively.

Operating cash flow ran at or above reported net income in seven of the last ten quarters, which suggests earnings are backed by real cash rather than accruals. The Q4 2025 ratio of 0.92 and Q1 2025 ratio of 0.92 are the exceptions and may reflect working capital timing rather than a structural weakness. Investors should monitor whether the conversion stays above 1.0 as the 3870 launch scales, since sustained conversion below parity would warrant a closer look at receivables and inventory.

Free Cash Flow Margins Recovering from Trough

As reported in financial statements, IRMD's free cash flow margin rebounded to 35.9% in Q1 2026 after falling to 3.0% in Q1 2025, with Q3 2026 at 28.4%.

The sharp 2025 trough in FCF margin was driven by elevated capex and an adverse working capital swing rather than weaker operations, as operating cash flow remained positive throughout. The recovery to the high-20s and mid-30s range suggests the business is again converting a large share of revenue into free cash. Because the margin is highly sensitive to capex timing, the trajectory should be judged on a multi-quarter basis rather than any single period.

Capital Intensity Low, Spending Lumpy

According to recent SEC filings, IRMD's capex ran at 19.0% of revenue in Q1 2025 and 20.8% in Q3 2024 but has fallen to 0.5% in Q3 2026, indicating a shift from build-out to maintenance spending.

The elevated capex of 2024 and early 2025 likely reflected facility or tooling investment supporting the product pipeline, while the current sub-2% intensity points to a largely maintenance-level spending profile. Depreciation of roughly $380K to $460K per quarter sits well below current capex in most periods, suggesting the asset base is being refreshed selectively rather than broadly. Investors should monitor whether capex re-accelerates to support next-generation hardware, as that would reset the intensity baseline.

Working Capital Swings Drive Quarterly Noise

Based on reported figures, IRMD's working capital change swung from a $3.9M outflow in Q4 2025 to a $1.4M inflow in Q1 2026, accounting for much of the quarterly variance in operating cash flow.

The large working capital swings relative to a roughly $5-8M quarterly operating cash base suggest that receivables, inventory, or distributor stocking timing is material to reported cash generation. The Q4 2025 outflow coinciding with a sharp rise in dividend payments of $8.6M is worth noting, as it may indicate year-end timing effects. Analysts should separate genuine demand-driven working capital build from channel inventory to judge whether cash conversion quality is durable.

Cash Returned Through Dividends, No Buybacks

As reported in financial statements, IRMD paid $2.6M in dividends in each of the most recent three quarters and $8.6M in Q4 2025 while reporting zero share repurchases and no acquisition spend across the period.

Capital return has been dividend-led, with payouts consuming a meaningful but affordable share of quarterly FCF of roughly $5-8M in recent periods. The absence of buybacks and acquisitions, combined with a cash balance above $51M, suggests management is retaining optionality rather than deploying capital aggressively. This may reflect a lack of suitable acquisition targets, which warrants further investigation given the company's stated focus on its niche.

What Cash Flow Statements Obscure

Based on the supplied quarterly data, stock-based compensation of roughly $650K to $800K per quarter is added back in operating cash flow, which flatters cash conversion relative to net income.

Because SBC is a non-cash expense, the operating cash flow figures are structurally higher than an economic cash view that treats equity compensation as a real cost. The SBC add-back reaches roughly 10-13% of quarterly net income in several periods, which may overstate the cash earnings power available to shareholders. Investors should monitor whether the conversion ratio holds when SBC is treated as an economic expense.

IRMD — Frequently Asked Questions

Quick answers to the most common questions about buying IRMD stock.

How much cash does IRadimed Corporation (IRMD) generate from operations?

IRadimed Corporation (IRMD) generated $24.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is IRadimed Corporation's free cash flow?

IRadimed Corporation (IRMD) generated $17.2M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is IRadimed Corporation's capital expenditure (CapEx)?

IRadimed Corporation (IRMD) spent $7.8M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does IRadimed Corporation distribute cash to shareholders?

In 2025, IRadimed Corporation (IRMD) returned $15.0M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.